Prof Brian O'Neill

So in this trial, this is called the INSPIRE trial,

which is sponsored by Cancer Trials Ireland and strongly supported by IROG, the Irish Research Radiation Oncology Group.

It's second generation prostate sabre where we're treating the tumour, there's often one or two tumours visible in the MRI, to the same or higher dose, but...

we're reducing dose to critical areas in the prostate to reduce side effects, in particular the urethra, the urine tube running through.

So the key point is that we're going to maintain the excellent results we've been seeing with Prostate Sabre, but we hope to do so...

and reduce side effects, especially urinary side effects.

It can do minorly, but it won't have an impact in terms of prostate cancer risk.

That's been looked at, actually.

And the answer is that none or regular neither have an impact.

Oh, okay.

So that's disappointing.

Would a PSA detect other problems?

It's actually quite specific to prostate.

It may detect prostate infection or inflammation, but it's specific to prostate.